UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 11, 2007
-------------
Enzo Biochem, Inc.
--------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Its Charter)
New York
--------------------------------------------------------------------------------
(State or Other Jurisdiction of Incorporation)
001-09974 13-2866202
--------------------------------------------------------------------------------
(Commission File Number) (IRS Employer Identification No.)
527 Madison Avenue
New York, New York 10022
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(212) 583-0100
--------------------------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
--------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
(a) The following information, including the Exhibit attached hereto, is being
furnished pursuant to this Item 2.02 and shall not be deemed "filed" for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor
shall it be deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended, except as shall be expressly set forth by specific
reference in such filing.
On June 11, 2007, Enzo Biochem, Inc., a New York corporation (the
"Company"), issued a press release discussing its financial results for its
third fiscal quarter ended April 30, 2007. A copy of the press release is
furnished as Exhibit 99.1 to this report.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press Release of Enzo Biochem, Inc., dated June 11, 2007,
discussing financial results for third fiscal quarter ended
April 30, 2007.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
ENZO BIOCHEM, INC.
Date: June 13, 2007 By: /s/Elazar Rabbani
---------------------------------------
Dr. Elazar Rabbani
Chairman of the Board and Chief
Executive Officer
EXHIBIT INDEX
Exhibit No. Description
99.1 Press Release of Enzo Biochem, Inc., dated June 11, 2007,
discussing financial results for third fiscal quarter ended
April 30, 2007.